Evidence map›Paper›PMID 33479645›Full record

ArticleRSC medicinal chemistry2020

Isoquinoline thiosemicarbazone displays potent anticancer activity with

Daniel L Sun, Soumya Poddar, Roy D Pan, Ethan W Rosser, Evan R Abt, Juno Van Valkenburgh, Thuc M Le, Vincent Lok, Selena P Hernandez, Janet Song and 16 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in RSC medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 1 institution in 3 countries.

Daniel L SunDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Soumya PoddarDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Roy D PanDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.ORCID 0000-0003-2840-283X
Ethan W RosserDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.ORCID 0000-0003-1060-7634
Evan R AbtDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Juno Van ValkenburghDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Thuc M LeDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Vincent LokDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Selena P HernandezDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.
Janet SongDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Joanna LiDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Aneta TurlikDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.
Xiaohong ChenDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.
Chi-An ChengDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.ORCID 0000-0002-6657-9137
Wei ChenDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.
Christine E MonaDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Andreea D StuparuDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Laurent VergnesDepartment of Human Genetics , David Geffen School of Medicine , University of California, Los Angeles , California 90095 , USA.
Karen ReueDepartment of Human Genetics , David Geffen School of Medicine , University of California, Los Angeles , California 90095 , USA.
Robert DamoiseauxUCLA Metabolomic Center , University of California, Los Angeles , Los Angeles , California 90095 , USA.
Jeffrey I ZinkDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.ORCID 0000-0002-9792-4976
Johannes CzerninDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Timothy R DonahueDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.
Kendall N HoukDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.ORCID 0000-0002-8387-5261
Michael E JungDepartment of Chemistry and Biochemistry , University of California, Los Angeles , California 90095 , USA . Email: jung@chem.ucla.edu.
Caius G RaduDepartment of Molecular and Medical Pharmacology , University of California, Los Angeles , California 90095 , USA . Email: cradu@mednet.ucla.edu.ORCID 0000-0002-9338-5397
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
PET Imaging-guided Personalized Therapy in Pancreatic CancerR01CA187678 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CZERNIN, JOHANNES, DONAHUE, TIMOTHY R · 2014 to 2018
$2.8M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA187678NCI NIH HHS T32 CA009120
6 · The paper itself

Abstract

A potent class of isoquinoline-based α-N-heterocyclic carboxaldehyde thiosemicarbazone (HCT) compounds has been rediscovered; based upon this scaffold, three series of antiproliferative agents were synthesized through iterative rounds of methylation and fluorination modifications, with anticancer activities being potentiated by physiologically relevant levels of copper. The lead compound,

Identifiers

PMID33479645
PMCPMC7593890
OpenAlexW3008903995

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.